Zafrens
Zafrens is a drug discovery company leveraging its proprietary Z-Screen platform, which replaces conventional experimental formats with a high-throughput system capable of processing 50,000 - 200,000 wells per day. This platform allows for the sequencing of every cell imaged in an assay, revealing causal relationships between perturbations, molecular responses, cell function, and interactions. Zafrens' technology enables simultaneous phenotypic and molecular screening for drug discovery through Active-Drug-seq, linking libraries of perturbations with phenotype and genotype at single-cell resolution. Their universal workflow accepts cells and beads as inputs, providing paired longitudinal imaging and sequencing data as outputs, significantly compressing drug discovery timelines.
Zafrens
Zafrens is a drug discovery company leveraging its proprietary Z-Screen platform, which replaces conventional experimental formats with a high-throughput system capable of processing 50,000 - 200,000 wells per day. This platform allows for the sequencing of every cell imaged in an assay, revealing causal relationships between perturbations, molecular responses, cell function, and interactions. Zafrens' technology enables simultaneous phenotypic and molecular screening for drug discovery through Active-Drug-seq, linking libraries of perturbations with phenotype and genotype at single-cell resolution. Their universal workflow accepts cells and beads as inputs, providing paired longitudinal imaging and sequencing data as outputs, significantly compressing drug discovery timelines.